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CHAPTER 1 - INTRODUCTION 
1.1 Ovarian cancer and the issue of missing heritability 
Ovarian cancer (OVCA) is the eleventh most common cancer amongst 
women and the fifth leading cause of cancer related deaths, with a five year 
survival rate of less than 50%(“Ovarian Cancer - Cancer Stat Facts,” 2018). 
According to the National Cancer Institute (NCI), since 1992 there has been a 
progressive decrease in the number of new cases of ovarian cancer, so prevention 
efforts have made an impact. However, this trend does not stand as strongly for 
the number of deaths due to OVCA.  OVCA is a rare form of cancer and the number 
of deaths from this disease has not changed in recent years. It is still ranked among 
the top 10 cancers in lethality attributed to its poor survival. The five year survival 
from 1992 – 2009 was 49.2% and remains almost the same in 2019. 
The different types of cancers of ovarian cancer are referred to by the cell 
type from they are derived from epithelial, germ cell and stromal. In addition, the 
subtype classification, pathologic grade, histology, are  factors in prognosis and 
treatment (Torre et al., 2018).  Epithelial ovarian cancer (EOC) can be classified 
histologically as serous, mucinous or clear cell. Additionally, EOC can be 
categorized as type I or II. Type I is considered to be a low-grade carcinoma with 
a higher survival rate and more associated with somatic mutations. In comparison, 
Type II EOC is more aggressive with a lower survival due to the spreading of the 
cancer cells beyond the ovaries, often with late-stage diagnosis (Torre et al., 





cancers encompassing germ cell, stromal tumors, small cell carcinoma and 
ovarian sarcoma. 
Approximately 25% of all EOC cases are considered to be hereditary but 
this figure is most likely an underestimation due to missing heritability (Bodmer & 
Tomlinson, 2010; Manolio et al., 2009). BRCA1 and BRCA2 are tumor suppressor 
genes and account for 5 – 10% of all OVCA cases (Ramus & Gayther, 2009). 
Hereditary EOC is part of the hereditary breast and ovarian cancer syndrome, 
which has an autosomal dominant inheritance pattern. Patients with a genetic 
predisposition of EOC are characterized by one or more of the following: family 
history of ovarian and/or breast cancer, Ashkenazi Jewish heritage, early age of 
onset, presence of BRCA1/2 mutations, and mutations in other DNA repair genes 
or mutated mismatch repair genes associated with Lynch syndrome (Saslow et al., 
2012). Current EOC patients that fit one or more of these classifications are 
recommended to undergo genetic testing of buccal or blood DNA. The panel for 
risk assessment of HBOC consists of 25 genes involved in DNA repair, cell cycle 
regulation, cell adhesion, RAS signaling, and enzymatic activity. The panel is a 
comprehensive testing tool for cancers including the breast, ovarian and uterine 
(Figure 1). However, panel testing is limited to the assessment for mutations 
already implemented in disease risk. This process does not allow for the discovery 
of novel risk mutations in panel genes or in genes that are part of the same 
pathway or have a similar function.  Whole genome or exome sequencing (WES) 
of patient blood and/or tumor DNA is required to identify germline variants that are 





pipeline optimized for accuracy and performance of next generation sequencing 
(NGS) analysis, variants of interest are identified based on the American College 
of Medical Genetics (ACMG) guidelines. While the progression of panel testing for 
genetic heritability of rare diseases and disorders has grown in the past decade, 







Figure 1: Risk genes associated with ovarian, breast and uterine carcinomas 





EOC individuals who have been diagnosed or are suspected to be at risk of 
the disease are recommended to undergo testing of their germline DNA for known 
pathogenic mutations in 25 ovarian and breast cancer associated genes (Figure 
1). Germline DNA is sequenced using next generation sequencing (NGS) 
technology and the raw data is processed and formatted to a variant call format 
(VCF) text file that stores gene sequences. In the case of germline variants, criteria 
to identify mutations of interest include low minor allele frequency, type of mutation, 
location of mutation, segregation data, evidence of cancer risk association in 
publically available databases that report on the relationships of human variation 
and phenotypes, genotype to phenotype literary evidence, algorithms that predict 
the impact of the variant, and conservation scores. All variants of interest are 
confirmed by Sanger sequencing to ensure that false positives are not reported as 
disease-causing. Clinical geneticists use the molecular genetic profiles to highlight 
the most significant findings to the patient including important variants found in the 
associated gene(s), the evidence used to interpret variant, and relevance of the 
findings to both the patient and family members.  
1.2 Variant Classification  
 Guidelines have been created by the American College of Medical Genetics 
(ACMG) to determine variant classification (Richards et al., 2015a). Variants can 
be classified into five groups; pathogenic, likely pathogenic, unknown significance, 
benign or likely benign.  Pathogenic or likely pathogenic variants are sub-classified 
as very strong, strong, moderate or supporting based on evidence for the particular 





classified as stand-alone, strong or supporting (Richards et al., 2015b). There are 
several different types of data that determines if a variant is pathogenic or benign. 
Population, computational, functional, segregation, de novo, allelic, other 
databases, population data, computational and functional data determines a 
mutations impact (Table 1) (Richards et al., 2015b). The purpose of benign sub-
classification is to ensure that the variant does not impact protein function and 
overall patient risk. Variants of unknown significance (VUS) are classified as such 
if there is conflicting evidence of the mutation being pathogenic or benign. The 
mutation may be novel, private or there is opposing evidence of its impact on 
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 X X X X X 
Functional 
data 
X  X  X  
Segregation 
data 
X  X X X  
De novo data     X  
Allelic data  X     
Other 
databases 
 X X    
Other data  X X    
 








1.3 Variants of unknown significance impacts missing heritability 
A primary contributor to the issue of missing heritability is variants of 
unknown significance (VUS) (Bodmer & Tomlinson, 2010). The mutations effect 
on protein function and the patient is not known (Richards et al., 2015b). Often, 
patients are made aware of a VUS after genetic testing. But they cannot be 
counseled due to the lack of information about the impact of the mutation on protein 
function (Richards et al., 2015b). Essentially there is a gap of knowledge that does 
not allow clinicians to counsel patients on their true genetic risk. An important step 
in evaluating the significance of a genetic lesion is to use a combination of 
computational and laboratory techniques. It has been proposed that instead of high 
throughput sequencing of a set of panel genes, whole genome (WGS) or whole 
exome sequencing (WES) is a more powerful method of assessing patients who 
are suspected to have a hereditary risk of cancer (Chaudhry, Stafford, Tainsky, & 
Levin, 2017). Clinicians can gain a better understanding of the genetic profile of 
patients, identify novel risk loci outside of the standard genetic panels and have 
the ability to re-visit the data (Chaudhry et al., 2017). The guidelines for variant 
assessment is constantly being updated by both National Comprehensive Cancer 
Network (NCCN) (Pilarski et al., 2018) and ACMG (Richards et al., 2015b). 
Therefore, reassessing WES/WGS patient data will ease the financial and 
resource burden of resequencing and data processing.  
1.4 The limitations of genome wide association (GWAS) studies 
A large portion of individual differences in disease susceptibility is due to 





approach to the prevention, diagnosis, and treatment of disease (Manolio et al., 
2009). A previous source of promise was conducting GWAS to identify pathogenic 
mutations from thousands of affected and/or unaffected individuals. Due to the 
rarity of OVCA, the frequency of the germline variants in the general population is 
quite low, but most allele thresholds for GWAS studies at least 5% of the population 
(Auer & Lettre, 2015). GWAS explains a small fraction of missing heritability 
because of the inability to identify causal variants and genes in complex traits (Tam 
et al., 2019). Also, GWAS studies have high false positives and low replication, so 
this methodology has fallen short in identifying novel risk loci associated with rare 
diseases such as OVCA (Auer & Lettre, 2015; Tam et al., 2019).     
1.5 Identifying novel risk loci TP53I3-S252* in HBOC patients 
 To address the issue of missing heritability in HBOC, WES is conducted on 
a cohort of 48 Caucasian women diagnosed with high-grade ovarian cancer. 
These woman have a personal history of breast cancer or a family history of breast 
and/or ovarian cancer (Stafford et al., 2017). During the time of sample retrieval, 
the guidelines for genetic testing for HBOC was limited to assessing for pathogenic 
mutations in BRCA1 and BRCA2. Thus, these women are an ideal cohort for up to 
date genetic panel testing to identify clinically actionable mutations. The cohort can 
also highlight the importance of identifying novel risk mutations in non-
panel/candidate genes.  After WES of the germline DNA, in silico single nucleotide 
(SNP) assessment is conducted to filter down to clinically actionable or candidates 
variants for functional assessment. There are 5 clinically actionable mutations in 





repair and cell cycle regulation (Lopes, Chaudhry, Lopes, Levin, & Tainsky, 2019; 
Stafford et al., 2017).  
Of particular interest is the pre-mature stop gain mutation in Tumor Protein 
p53 Inducible Protein 3 (TP53I3). The nonsense mutations is found in two of the 
48 patients, OCJ19 and OCG14. The TP53I3 gene is unique because it is a 
quinone oxidoreductase (Porté et al., 2009), involved in the DNA damage 
response (Contente, Dittmer, Koch, Roth, & Dobbelstein, 2002; B. Li et al., 2013), 
and p53-mediated apoptosis (Lee et al., 2010; Polyak, Xia, Zweier, Kinzler, & 
Vogelstein, 1997). Identifying the truncation in TP53I3 resulted in the expansion of 
in silico SNP assessment to include genes that are part of the conserved 
programmed cell death pathway way, apoptosis.  
1.6 TP53I3 function in apoptosis and oxidative stress  
1.6.1 Functional overview 
TP53I3, formally known as PIG3, is located on chromosome region 2p23.3 
(Figure 2). It was originally discovered as a downstream transcriptional target of 
p53 prior to the understanding of its role in apoptosis (Polyak et al., 1997). Its 
coding region consists of 5 exons and there are two full-length mRNA variants with 
different 5’UTR regions. At the N-terminus, there exists a nuclear localization 
sequence (Lee et al., 2010). The C-terminus is homologous with quinone 
oxidoreductases (QOR) (Porté et al., 2009). Alternative pre-mRNA splicing events 
can cause the skipping of exon 4 and result in the splice variant PIG3AS (Nicholls 
et. al., 2004). TP53I3 is found in most vertebrates except rodents, but it is present 





gene TED2 which is a plant NADPH oxidoreductase and involved in the formation 
of plant meristems by apoptosis (Polyak et al., 1997). In mammals, the TP53I3 
sequence is most similar to NADPH-quinone oxidoreductase, ζ-crystallin, a potent 
generator of reactive oxygen species (ROS) (Porté et al., 2009). Therefore, TP53I3 
is a QOR which is part of the medium chain reductases (MDR) superfamily. The 
coding sequence contains a conserved binding motif for medium chain 
dehydrogenases/reductases (MDR). There are also 13 residues in the amino acid 
sequence of TP53I3 that NADP+ can bind to, 7 of which are conserved (Porté et 
al., 2009). TP53I3 has also been associated with DNA damage response by 











Figure 2: TP53I3 gene structure and domains 
TP53I3 is located on chromosome 2p23.3 and is 1653 nucleotides in length. There 
are two p53 binding sites at the promoter region including the polymorphic 
microsatellite (TGYCC)n. The nuclear localization site is close to the N-terminus 
and the homologous MDR superfamily sequence is near the C-terminus. There 
are 13 NADP+ binding sites, all within the sequence that shares homology with the 







1.6.2 Three-dimensional structure of TP53I3 proposed in 2009 
In 2009 the crystallographic structure of TP53I3 was determined in the 
presence of NADP+ to determine the protein’s enzymatic function (Porté et al., 
2009).  The following will explain the protein structure and important domains. Two 
constructs were crystallized and had identical subunits making the TP53I3 a stable 
homodimer. The protein structure contains two important domains, a catalytic 
domain (Met1 – Ala119 and Leu265 – Gln332) and a cofactor-binding domain 
(Ala120 – Ser264). In-between these two domains is a deep cleft for the NADP+ 
molecule to bind to. There are 13 amino acid residues that can bind to NADP+, 7 
of which are conserved in the TP53I3 sequence.  One of the binding sites for 
NADP+ resides in the conserved binding motif (A/G)XXSXXG and can be found in 
many other quinone oxidoreductases (Edwards et al., 1996). A missense change 
from a serine to a valine (TP53I3-S151V), results in enzymatic inactivation due to 
steric hindrance and preventing NADP+ from binding. NADPH binding to TP53I3 
was determined by the quenching of protein fluorescence, the 2’ phosphate group 
binds to Gly173, Lys173, and Tyr192. Many NADPH dependent MDRs are 
characterized by having a glycine at the C-terminal end of the nucleotide binding 
domain. The corresponding residue in TP53I3 would be the conserved Gly173. 
This suggests that TP53I3 is an NADPH dependent enzyme.  
 The active binding site is formed by amino acids Asn40, Ala42, Met45, 
Tyr51, Leu51, Leu63, Glu123, Thr127, Leu63, Glu123, Thr127, Leu240, Leu255, 
Phe256, and Leu265. TP53I3 NADPH-dependent reductase activity was tested 





enzymatic activity with 1,2-naphthoquinone (1,2-NQ), an ortho-quinone. Kinetic 
analysis was conducted with wildtype TP53I3 or TP53I3-S151V in the presence of 
the 1,2-NQ  substrate (Porté et al., 2009). The Vmax determines the rate of reaction 
when the substrates saturate the enzyme and is dependent on the affinity of the 
substrate to bind to the enzyme.  To determine if a substrate has a high binding 
affinity with an enzyme, the Michaelis constant is measured (Km) (Johnson & 
Goody, 2011). The Km measures the concentration of the substrate which permits 
the enzyme to achieve half Vmax. The second order rate constant Kcat/Km is the 
catalytic efficiency of the enzyme (Johnson & Goody, 2011). The Kcat/Km for 
TP53I3-S151V in the presence of 1,2-NQ was much higher than wildtype TP53I3 
indicating the mutant is enzymatically inactive (Porté et al., 2009).  
The structure of 1,2-NQ substrate fits into the active binding site of TP53I3 
in the appropriate orientation. The production of ROS was detected in the presence 
or absence of 1,2-NQ substrate, TP53I3 enzyme and/or cofactor NADPH. There 
was a significant increase in ROS production after a complete reaction consisting 
of the enzyme, substrate, and cofactor, compared to when there was an absence 
of one of the components. Intracellular ROS was measured with the 2’,7’-
dichlorodihydrofluorescein diacetate (DCFHDA) in HCT-116 with unmodified 
TP53I3, overexpressed TP53I3, TP53I3-S151V or phorbol 12-myristate 13-
acetate (PMA; positive control).  The TP53I3-S151V mutant resulted in a 
significant decrease in intercellular ROS production compared to cells with 





can affect binding affinity for ortho-quinone substrates, causing a hindrance in 
ROS production. 
1.6.3 Transcriptional Regulation of TP53I3 
There are two p53 binding sites in the promoter region of TP53I3 (Figure 
2). The first is 308 nucleotides upstream of the transcription start site and is the 
classic 20 base pair p53 binding sequence. The second preferential binding site, 
is the polymorphic penta-nucleotide microsatellite sequence (TGYCC)n positioned 
between 412 and 517 nucleotides downstream of the transcription start site 
(Contente et al., 2002). The microsatellite is considered to be the first of its kind to 
functionally interact with a transcription factor (Contente et al., 2002). Variations of 
these repeat sequences have been associated with many different cancers 
including squamous cell carcinoma of the head and neck (Guan et al., 2013), 
myeloid leukemia (Nomdedéu et al., 2004), breast carcinoma (Gorgoulis et al., 
2004), lung carcinoma (Gorgoulis et al., 2004) and invasive bladder cancer (Ito et 
al., 2006). There were four different motif sizes found in a population of healthy 
individuals, 10, 15, 16 or 17 with a frequency of 5.1%, 63%, 21.4%, and 11.5% 
respectively. The greater the number of TGYCC repeats, the stronger the 
interaction with p53 (Contente et al., 2002). Transcriptional activation of TP53I3 
can also be regulated by p63 and p73 through the penta-nucleotide microsatellite 
region and mutated p53 also interacts with the motif but not as strongly (Contente 
et al., 2002). 
TP53I3 is also transcriptionally regulated by alternative splicing, resulting in 





of the splice variant (PIG3AS) with the full-length variant (Nicholls et al., 2004). 
The splice variant is made up of 248 amino acids lacking most of the 5’UTR region. 
Unlike the full-length variants, the PIG3AS C-terminal domain is not homologous 
with QOR (Kotsinas et al., 2012). Under normal conditions, there is a preference 
for the expression of the full-length variant. However, under ultra-violet irradiation, 
there is a preference for expression of PIG3AS which has a short life span and is 
considered non-functional (Nicholls et al., 2004). Therefore, it is possible that 
defects in the C-terminus of the full-length variant will, at the very least, affect ROS 
production and cellular apoptosis.  
1.6.4 Apoptosis 
To fully appreciate the role of TP53I3 in apoptosis, a basic understanding 
of the mechanism is necessary. Apoptosis is an essential mechanism that initiates 
the programming of cell death and the maintenance of tissue homeostasis. There 
are many forms of programmed cell death, and apoptosis is thought to be of 
particular importance and distinction (Elmore, 2007). Apoptosis is a defense 
mechanism when cells are stressed by DNA damage, external toxins, and reaction 
to the immune system (Norbury & Hickson, 2001). In mouse models, it has been 
demonstrated that apoptosis and necrosis can occur independently, sequentially 
or simultaneously (Zeiss, 2003). To differentiate between the two processes, 
morphological differences can be assessed. Necrosis is characterized by cell 
swelling and dissolution of the nucleus. On the other hand during apoptosis, cells 
shrink, cytosol calcium increases, and the nucleus becomes dense and compact 





regulator of  tumorigenesis and treatment response (Fulda & Debatin, 2006). 
Drugs or irradiation used to target cancer cells can damage the DNA and lead to 
p53-mediated apoptosis (Elmore, 2007).   
1.6.5 Intrinsic apoptosis  
There are two main apoptotic pathways, extrinsic/death receptor and 
intrinsic/mitochondrial. Damage to the cell’s DNA elicits apoptosis primarily 
through the intrinsic pathway (Figure 3). The intrinsic or mitochondrial pathway, is 
of particular interest because it involves upstream transcriptional activation of p53-
mediated apoptosis cells. Recall, TP53I3 is transcriptionally activated by p53 
binding to the polymorphic pentanucleotide repetitive motif (TGYCC)n to initiate 
apoptosis. Components involved in the apoptosis process are conserved proteins 
and physical association with the mitochondria. In terms of the intrinsic pathway, 
when pro-apoptotic signals occur, disruption in the mitochondrial membrane 
potential causes the release of cytochrome c into the cytoplasm (Elmore, 2007). 
Cytochrome c pairs with apoptotic protease activating factor 1 (APAF1) and 
inactive caspase-9, forming the apoptosome (Elmore, 2007). The apoptosome 
hydrolyzes adenosine triphosphate (ATP) to cleave and activate. Activated 
caspase-9 cleaves and activates caspases- 3, 6 and 7 followed by cell apoptosis 
(Norbury & Hickson, 2001). Cleavage and activation of caspase-3 is the hallmark 
of apoptosis because it promotes DNA fragmentation and cell death (Cotter, 2009). 
Permeabilization of the mitochondria membrane also releases Smac into the 
cytosol which promotes apoptosis by blocking inhibitors of apoptosis proteins 





regulators of intrinsic apoptosis. The Bcl-2 family activates pro-apoptotic or inhibits 
anti-apoptotic genes. Some of the best characterized pro-apoptotic proteins are 
BID, BAD, BIM, BMF, Puma and NOXA contain a Bcl-2 homology 3 domain (BH3) 
(Kluck et al., 1999). Anti-apoptotic proteins BCL-2, BCL-XL, and MCL-1 have 









Figure 3: Intrinsic apoptosis pathway 
Image source: https://www.creative-diagnostics.com/intrinsic-apoptosis-






1.6.6 p53-mediated apoptosis  
Tumor protein p53 regulates the expression of many genes involved in a 
variety of cellular mechanisms including apoptosis, growth arrest, and 
senescence. The protein consists of four conserved domains, N-terminus, 
sequence-specific DNA binding, tetramization domain, and C-terminus (Pavletich, 
Chambers, & Pabo, 1993). When cells are stressed, p53 is stabilized and 
accumulates in the nucleus. Phosphorylation of p53 is mediated by cellular kinases 
including check point kinase 1 (CHK1) and check point kinase 2 (CHK2) as well as 
ataxia-telangiectasia mutated (ATM) (Kuribayashi et al., 2011; Schuler & Green, 
2001). Activated p53 initiates the expression of genes leading to programmed cell 
death (Shen & White, 2001). To promote apoptosis, p53 transcriptionally activates 
a specific set of genes known as p53-proapoptotic genes including TP53I3 and 
TP53AIP1 as well as BID, PUMA, NOXA, BAD, BAX, CASP6, and APAF1 
(Kuribayashi et al., 2011). Depending on which residue is phosphorylated or 
acetylated in p53, certain pro-apoptotic genes are selectively expressed. 
Phosphorylation of serine 15 and 20 (Amano et al., 2009) or acetylation at 320 and 
373 results in the transcriptional activation of TP53I3 (Yanagihara et al., 1991). A 
subset of p53 targeted apoptosis genes also function as ROS producers, including 
TP53I3. While p53 is often mutated or not functional in tumors, family members 






1.6.7 Quinone reduction reaction for ROS production and downstream 
apoptosis 
Low levels of ROS are important for normal cell cycle progression, 
proliferation, differentiation, migration, death (Covarrubias et a., 2008), immune 
response and redox reaction regulation (Schieber & Chandel, 2014). Excessive 
levels of cellular ROS are detrimental to cellular integrity and can trigger oxidative 
stress. Increased production of ROS has been associated with cancer, metabolic 
and neurodegenerative diseases (Kehrer & Klotz, 2015). Production of ROS 
involves endogenous or exogenous factors. Endogenous superoxide ROS 
production occurs due to leaks in the mitochondrial electron transport chain, 
specifically from complex I and II (Dickinson & Chang, 2011).  Superoxides are 
also produced by NADPH oxidases, xanthine oxidases, and cytochrome P450 
reductases (Bae, Oh, Rhee, & Yoo, 2011). The TP53I3 protein is a quinone 
oxidoreductase due to sequence with similarity with the QOR family and reactivity 
with quinone substrates for ROS production (Porté et al., 2009). Under normal 
conditions, TP53I3 is localized in the cytosol, a feature shared with other QOR 
(Flatt et al., 2000).  
 Oxidative stress is an imbalance between pro-oxidative and anti-oxidative 
states that leads to an increase in ROS (Schieber & Chandel, 2014). Oxidative 
stress is commonly associated with causing cellular damages to age-related 
processes such as cancer (Klaunig & Kamendulis, 2004).  The mechanism can be 
initiated through the redox reaction cycle that involves many oxidoreductases 





redox reaction by regulating ROS production (Gorrini, Harris, & Mak, 2013; 
Srinivas, Tan, Vellayappan, & Jeyasekharan, 2019). During respiration, about 5% 
of molecular oxygen is converted to ROS. Major ROS molecules include 
superoxide (O-), H2O2, and hydroxyl radical (OH) (Pelicano, Carney, & Huang, 
2004). Production of ROS changes the cellular redox state and effects the 
modification of nucleic acid, proteins, and lipids which are important processes for 
cancer progression. The redox cycling of quinones is initiated by oxidoreductases, 
included NADPH-dependent quinone reduction and the understudied class of 
QOR belonging to the MDR superfamily (Oppermann, 2007). Quinone compounds 
are reduced to unstable intermediates semiquinone, by one electron, or to 
hydroquinone by two electrons. Reduction to hydroquinone also requires the 
presence of quinone reducing agents such as NADPH-oxidoreductase (Figure 3) 
(Bolton & Dunlap, 2017; Oppermann, 2007; Porté et al., 2009). The reduction of 
oxygen generates superoxide ROS which is dismutated by superoxide dismutase, 
generating H2O2. The compound is then reduced to another form of ROS, hydroxyl 
radicals, in the presence of a metal ion (Bolton & Dunlap, 2017).  Quinones can 
sustain the production of ROS leading to DNA modifications and affecting cellular 
response and defense mechanisms such as apoptosis.  
Potent levels of ROS increases the amount of intrinsic apoptosis (Redza-
Dutordoir & Averill-Bates, 2016). High amounts of ROS can activate p53 or JNK 
resulting in the activation of Bcl-2 proteins. Oxidation of cardiolipin and the 
depolarization of the mitochondrial membrane releases cytochrome c into the 





the apoptosome triggering the downstream caspase cascade activation effect and 

















1.6.8 How TP53I3 connects oxidative stress and DNA Damage Response 
(DDR) 
In order for DDR proteins such as TP53I3 to properly function, recognition 
of DNA breaks by ATM is required. The protein kinase then activates the p53 
antitumor cellular response causing cell cycle arrest, apoptosis or senescence. 
Also activated by p53 are DNA repair mechanisms that are compromised in 
malignant cells. Because TP53I3 has a role in two conserved mechanisms, it is 
thought that loss of function could be toxic to both normal and cancer cells (A 
Kotsinas et al., 2010). 
There is a proposed model for how TP53I3 functions in normal and 
malignant cells that ties together the effects of oxidative stress and DDR (A 
Kotsinas et al., 2012).  In normal cells under genotoxic stress, DNA damage 
response (DDR) stabilizes p53 and TP53I3 expression is increased. During low 
levels of genotoxic stress, DDR TP53I3 triggers DNA repair. When DNA is 
exposed to genotoxic stress, p53 increases the expression of pro-oxidant TP53I3 
even more. This causes lethal levels of ROS production and eventual cellular 
apoptosis. When malignant cells with wildtype p53 are under continuous oxidative 
or genotoxic stress, mutations accumulate. A significant amount of TP53I3 is 
shuttled to the nucleus to support DDR which adds to the sub-lethal ROS 
production, maintaining the oxidative stress conditions. The continuous support of 
DDR by TP53I3 leads to p53 loss or mutation. However, p63 or p73 can 
compensate for the loss of p53 to support the positive feedback loop of TP53I3 





1.6.9 DNA damage response 
DDR involves the mechanisms that sense and signal the  presence of DNA 
(Harper & Elledge, 2007). DNA repair processes include proteins that are highly 
conserved. Mutations in these proteins can lead to defects in DNA repair and 
increase predisposition to cancer. Types of DNA damage include bases mismatch, 
single strand breaks, double strand breaks (DSB), insertions, deletions, bulky DNA 
lesions, oxidized/deaminated bases, methylated (O6 or N7) guanine, pyrimidine 
dimers, interstrand crosslinks and intrastrand crosslinks (Blanpain, Mohrin, 
Sotiropoulou, & Passegué, 2011; Pilié, Tang, Mills, & Yap, 2019). Two 
mechanisms involved in DSB are non-homologous end joining (NHEJ) and 
homolgous recombination repair (HRR). Many genes that drive HRR are part of 
the HBOC panel, including   BRCA1, BRCA2, ATM, CHK2, PALB2, RAD50, 
RAD51D, and NBN  (da Cunha Colombo Bonadio, Fogace, Miranda, & Diz, 2018; 
Liang, Han, Romanienko, & Jasin, 1998).  
 DSB are made by damaging agents like ionizing radiation, radiomimetic 
drugs (Limoli, Giedzinski, Bonner, & Cleaver, 2002), replication blocking lesions 
(Bosco et al., 2004); ROS production (Srinivas et al., 2019) and topoisomerase I 
and II inhibitors (Degrassi, Fiore, & Palitti, 2004). The inability to repair DSBs can 
increase cell death or cause chromosomal changes causing genomic instability 
and the production of cancer cells (Shrivastav, De Haro, & Nickoloff, 2008). The 
presence of DNA double stranded breaks (DSBs) in eukaryotic cells can be 
repaired by two main mechanisms, HRR or NHEJ.  Homologous recombination 





less chance of spontaneous mutation formation compared to NHEJ repair (Liang 
et al., 1998). The determination for which mechanism should be used depends on 
how the double-stranded break (DSB) was created. For example, if replication fork 
stalling is recognized by the Fanconi Anemia complex, and will eventually lead to 
the signaling of BRCA1 for repair by HRR (Goldstein & Kastan, 2015). On the other 
hand, DSBs formed by IR can be repaired by HRR or NHEJ either pathways. HRR 
is a highly conserved mechanism due to the exchange of genetic information 
between allelic sequences (Liang et al., 1998; San Filippo, Sung, & Klein, 2008; 
Sung & Klein, 2006). HRR is vital for DNA repair, replication, meiotic chromosome 
segregation, and telomere maintenance. The HRR mechanism involves the 
broken ends of the DNA to use the homologous sequence as am repair template, 
from the sister chromatid or foreign DNA at the S and G2 cell cycle phase.  
When a DSB is detected, ATM phosphorylates H2AX histone family 
member X (H2AX). The DNA damage checkpoint protein 1 (MDC1) binds to the 
phosphorylated γH2AX and accumulates at sites of DNA damage. DSB repair 
proteins MRE11, RAD50 and NBS1 form the MRN complex which localizes to the 
DSB for stabilization and prevention of chromosome breaks. The 5’exonuclease 
activity of C-terminal binding protein-interacting protein (CtIP) creates single-
stranded overhangs and the replication protein (RPA) binds to the 3’ single-
stranded overhangs (Symington, 2014). RPA is replaced by RAD51, breast cancer 
1 (BRCA1) and 2 (BRCA2) proteins to create filaments on the DNA. A homologous 
sequence from the sister chromatids or foreign DNA is identified by the 3’ overhang 





(PCNA) produces the deleted DNA fragment which was once broken. Lastly, a 
Holliday junction is made after the formation of the new DNA fragment and the 







Figure 5: Homologous Recombination Repair (HRR) mechanism  
Image source: https://doi.org/10.3389/fgene.2019.00551. Permission of image use 
granted by Dr. Wen-Tao Ma from the Department of Preventative Veterinary 






Mutations in genes involved in DBS repair can be more detrimental than 
exogenous factors, whether they occurred in the germline or somatically. 
Approximately 40-50% of all ovarian cancers exhibit a deficiency in homologous 
recombination repair mechanisms (Elvin et al., 2017). Germline mutations in 
BRCA1 and BRCA2 are key in disrupting HRR (da Cunha Colombo Bonadio et al., 
2018). Breast and ovarian cancer were initially associated with HRR impairment 
due to mutations in BRCA1 and BRCA2 (da Cunha Colombo Bonadio et al., 2018; 
Miki et al., 1994; Wooster et al., 1995).  Other HRR genes associated with cancer 
risk include RAD51, CtIP, RAD51B, RECQL4, BLM, WEN and NBS1 (Helleday, 
2010). The expression of RAD51 is correlated with increased responsiveness to 
topoisomerase II inhibitor etoposide (Helleday, 2010). Platinum-based therapies 
are another standard of care with HBOC patients because of mutations in HRR or 
Fanconi Anemia genes, and are very responsive to treatment (Whitby, 2010). 
Targeted therapy regimens incorporating the use of PARP inhibitors are also 
beneficial for patients who carry germline mutations in either BRCA1 or BRCA2 
(Coleman et al., 2015).  
The role of TP53I3 in the DNA repair mechanism is not well defined. 
However, our recent work determined that it is involved in HRR (Lopes et al., 
2019). The knockdown of TP53I3 in HeLa-DRGFP cells resulted in a significant 
decrease in HRR induction (Lopes et al., 2019). Approximately 30% of TP53I3 is 
localized in the nucleus and the other 70% in the cytosol (Lee et al., 2010). 
Knockdown of TP53I3 in U2OS and HeLa cells negatively affects the intra-S phase 





al., 2010). Additionally, TP53I3 depletion increased cell sensitivity to UV and 
radiomimetic drugs. Under normal conditions when DDR signaling occurs TP53I3 
co-localizes with p-H2AX and 53BP1. When expression of TP53I3 is lost in cells, 
in the presence of genotoxic stress, there is significant reduction in  CHK1, CHK2 
and γH2AX (Lee et al., 2010). Breast cancer patients with high expression of 
TP53I3 and BRCA1 have a significantly higher overall survival. BRCA1 is also 
thought to regulate TP53I3 in a p53-dependent manner (Zhang et al., 2015). In 
HCT116 cells, overexpression of BRCA1 increased expression of TP53I3 and p53. 
In p53-null HCT116 cells, overexpression of BRCA1 did not induce TP53I3 
expression (Zhang et al., 2015). Added to the fact that two of our HBOC patients 
carry a TP53I3 germline truncation (Chaudhry et al., 2017; Lopes et al., 2019; 
Stafford et al., 2017), it would be beneficial to determine the effect of that mutation 
on repair of DSB with HRR for potential targeted therapy options.  
1.6 Personalized therapy in clinical cancer care 
There are two major issues with chemotherapy, drug resistance and relapse 
of the patient after remission (Leary, Heerboth, Lapinska, & Sarkar, 2018). One 
solution to mitigate both problems is personalized cancer care based on a patient’s 
molecular genetic profile. Additionally, targeted therapy can result in improved 
patient outcome. Cancer cells are most sensitive to drugs that do not allow for 
repair of DNA breaks so that they can eventually die due to the potent amount of 
damage. In many cancers, including breast and ovarian, one of the standard 





Pennington et al., 2014; Reed, 1998). However, platinum-based therapies can 
often lead to resistance or reoccurrence (Moiseyenko et al., 2014). 
Another chemotherapy drug given to HBOC patients is the topoisomerase 
II inhibitor etoposide, which targets HRR-deficient cells and is involved in ROS 
production. Relapsed EOC patients are often given a treatment regimen that 
incorporates the usage of etoposide (Konstantinopoulos, Ceccaldi, Shapiro, & 
D’Andrea, 2015). Etoposide treatment of EOC with BRCA1/2 mutations have a 
higher response, longer time to resistance and better overall survival (Safra et al., 
2011). Radiomimetic drug bleomycin inhibits DNA synthesis, B-cell, T-cell and 
macrophage proliferation (Muller, Yamazaki, Breter, & Zahn, 1972). Bleomycin 
also reacts with oxygen to form superoxide and hydroxide ROS (Wallach-Dayan 
et al., 2006). It is often used in combination with etoposide and/or cisplatin. 
Mitomycin C (MMC) is a chemotherapy drug that alkylates DNA to inhibit synthesis 
and forms interstrand cross-links like the platinum based drug cisplatin. It is a 
treatment option for anal, bladder, breast, cervical, colorectal, head and neck and 
non-small cell lung carcinomas. Ovarian cancer patients with germline BRCA1/2 
mutations have had a complete response, partial response or disease stabilization 
to MMC (Moiseyenko et al., 2014). 
1.6.1 Cancer therapies targeting intrinsic apoptosis  
 Most of the cancer therapies generate pro-death signals that initiate 
apoptosis of tumor cells. Apoptosis is no longer reversible once the outer 
membrane of the mitochondria is permeabilized (Elmore, 2007). Defects in the 





can result in resistance. Discovering new therapies that target genes involved in 
intrinsic mitochondrial apoptosis would be revolutionary in mitigating 
chemotherapy resistance. TP53I3 is a p53 regulated pro-apoptotic gene and part 
of a larger group of genes involved in regulating mitochondrial membrane potential. 
Additionally, its role in reacting as an enzyme in the presence of other quinone 
substrate contributes to ROS production under normal and stressed cellular 
conditions (Athanassios Kotsinas et al., 2012). Thus, with what is known about 
chemotherapy resistance, mutated TP53I3 could result in chemotherapy 
resistance and become the bases for creating new therapies to target intrinsic 
apoptosis. 
1.7 Functional assessment of TP53I3-S252* to address missing heritability 
The issue of missing heritability creates a knowledge gap in determining 
and understanding an individual’s true genetic risk of HBOC. A streamlined method 
of identifying novel risk loci is used in this study to exemplify the advantages of 
using NGS data analysis and wet lab techniques in combination. I conducted in 
silico assessment of 48 Caucasian non-Finnish women diagnosed with ovarian 
cancer and a personal or family history of epithelial cancers. WES analysis 
identified 13 truncations in apoptosis genes, including a rare pre-mature stop-gain 
mutation TP53I3-S252* (Stafford et al., 2017) in two patients. The truncation in 
TP53I3 will be functionally assessed in vitro to determine its impact on cancer 
related pathways DNA repair and apoptosis, as well as determining sensitivity or 
resistance to chemotherapy.  The nonsense mutation is upstream of three residues 





(Porté et al., 2009). When a QOR binds to the enzyme at the active site, ROS is 
produced in order for damaged cells to undergo apoptosis. Therefore, the TP53I3-
S252* truncation could prevent the substrates from binding to the active site and 











CHAPTER 2 – METHODS  
1.1 Acquiring Samples and Determining Tumor Histology 
Patient samples were acquired through the Karmanos Cancer Institute 
Genetic Registry (KCIGR).  An IRB was approved for bio-specimens from females 
with a personal or family history of breast and/or ovarian cancer.  From 1999-2013 
over 800 DNA samples were collected at which time HBOC genetic screening only 
involved BRCA1/2 risk assessment using BRCAPRO and Myriad II. BRCAPRO is 
a Bayesian model that determines the probabilities that a patient’s BRCA1 or 
BRCA2 mutation accounts for the pattern of breast and ovarian cancer in first- and 
second-degree relatives (Parmigiani, Berry, & Aguilar, 1998). Myriad II identifies 
putative BRCA1/2 mutation carriers based on patient ethnic ancestry (Ashkenazi 
Jewish or non-Ashkenazi Jewish), breast cancer age of onset (age ≤50 years), and 
the presence of ovarian cancer in the patient or first- or second-degree relatives 
(Frank, 1999).  
Of the 800 DNA samples, 89 were from high-risk Caucasian women with a 
personal history of OVCA. Participants were BRCA1/2 mutation carriers or 
BRCA1/2 wildtype after full gene sequencing, BART (BRCAnalysis rearrangement 
test) or testing for the three common Ashkenazi Jewish mutations. Participants 
who tested positive for pathogenic BRCA1/2 germline mutations were excluded 
from our study sample, resulting in a final count of 48 Caucasian women with one 
mother-daughter pairing. All subjects gave informed consent, allowing for the 





(HIC#024199MP2F(5R)) was approved following a Full Board Review by the 
Human Investigation Committee at Wayne State University, Detroit, Michigan. 
Classification of tumor histology included 26 serous, 5 endometrioid 
carcinoma, 4 adenocarcinoma, 1 mucinous, 1 clear cell and 9 undefined/unknown. 
Tumor grades included 6 moderately differentiated, 24 poorly differentiated and 1 
well differentiated. Primary diagnosis was determined to be ovarian cancer for 43 
patients with a secondary diagnosis of breast cancer (n = 6), colon cancer (n = 2), 
uterine cancer (n = 1) or melanoma (n = 1). The other 5 patients had a secondary 
diagnosis of OVCA, with primary being breast cancer (n = 4) or cervical cancer (n 






Histology N % 
Serous 26 54 
Endometrioid 5 10 
Mixed 4 8 
Adenocarcinoma, NOS 2 4 
Clear Cell 1 2 
Mucinous 1 2 
Unknown 9 19 
Stage N % 
I 8 17 
II 5 10 
III 23 48 
IV 3 6 
Unknown 9 19 
Grade N % 
Grade 1 1 2 
Grade 2 6 13 
Grade 3 31 50 
Unknown 17 35 
Personal and Family History N % 
Personal BC/OVCA diagnosis <50 years of age 15 31 
Personal second primary cancer diagnosis 12 25 
Personal/family history BC 31 65 
Family history of OVCA 14 29 
Family history of epithelial cancer 47 98 
Table 2: Tumor Histology and prevalence of ovarian cancer (OVCA)and 





1.2 Whole exome sequencing and candidate gene analysis 
DNA from peripheral blood samples was isolated by the Karmanos Applied 
Genomics Technology Center, Detroit, MI using Qiagen QIAamp DNA mini kit and 
WES was performed using Illumina Nextera Rapid Capture Kit. Samples were 
processed as followed: 
1. Samples were demultiplexed with Illumina CASAVE 1.8.2. 
2. Read quality assessment was conducted with with FastQC (Andrews, 
2010). 
3. Alignment to the human reference genome (hg19) (Lander et al., 2001) 
using Burrows Wheeler Aligner (BWA) (H. Li & Durbin, 2009). 
4. For the removal of PCR duplicates, samtools was utilized (H. Li et al., 2009). 
5. Local realignment, Qscore recalibration, variant calling, and filtering was 
performed using the GATK Unified Genotyper (DePristo et al., 2011). 
6. Subsequent filters were implemented to remove SNPs of low quality, read 
count or confidence: 
a.  SNP mapping quality = 0 for four or more alignments and the 
number of alignments that mapped ambiguously were in more than 
1/10 of all alignments. 
b. SNP reads less than 5 reads. 
c. SNP quality is less than 50  
d. QD score (variant confidence) is less than 1.5  
7. Variant Call Format (VCF version 4.1) files were created with Genome Trax 





8. Illumina BaseSpace VariantStudio application v2.2.4 and iVariantGuide 
were used for variant annotated and predicted variant effects was 
determined with snpEff (Cingolani et al., 2012). 
Our focus was to identify clinically actionable and novel loci in the 25 genes 
currently on the HBOC genetic testing panels by Ambry OvaNext and Myriad 
MyRisk. Also included were non-panel genes important to DNA damage response, 
cell cycle regulation or apoptosis and genes disease causing mutations associated 
with OVCA designated by HGMD (Table 3). To determine the impact of a variant 
on cancer risk, various clinically curated databases and bioinformatics tools were 
used including ClinVar (Landrum et al., 2018), HGMD (Stenson et al., 2017), 
COSMIC (Forbes et al., 2008), dbSNP (Sherry et al., 2001), gnomAD (Karczewski 
et al., 2019), SIFT (Ng & Henikoff, 2003), and PolyPhen (Adzhubei, Jordan, & 
Sunyaev, 2013). To focus on the most interesting variants very conservative filters 
were applied: 
1. Only exonic SNPs  
2. Moderate to high impact on protein function (frameshift, nonsense, and 
missense)  
3. A minor allele frequency of the mutations is less than 0.02 rare in the 
European, non-Finnish population 
4. Predicted to be damaging by predictive algorithms SIFT and/or PolyPhen, 
Variants that fit these criteria were confirmed by forward and reverse strand 






Table 3: List of DNA repair, cell cycle regulation and apoptosis genes 





1.3 Confirming variants of interest 
Validation of SNPs involves PCR amplification and Sanger sequencing. 
Primers targeted the genomic DNA in the patient carrying the SNP were created 
using Primer3Plus and Thermo Fisher Primer Designer Tool application. Primer 
constructs were obtained from Sigma-Aldrich.  Forward and reverse primers were 
between 200 – 100 base pairs away from the SNP, had a GC content of 
approximately 50% and annealing temperature between 50ºC and 52 ºC (Table 
4).  
1.3.1 PCR amplification  
Primers were re-suspended in sterile water for a stock concentration of 100 
µM and a working stock is diluted to 10 µM. PCR amplification was conducted 
using the QIAGEN Fast Cycling PCR Kit (203743).  
One reaction 20 µL consists of: 
1. 10 µL Qiagen Fast Cycling PCR Master Mix 
2. 2 µL CoralLoad Dye 
3.  2 µL forward primer (10 µM) 
4. 2 µL reverse primer (10 µM) 
5. 2 µL sterile H2O 
6.  2 µL of 25 ng/uL patient DNA/positive control/ negative control. The 
Positive control consists of normal fibroblast genomic DNA and the negative 
control was water.  
PCR amplification protocol requires denaturing, annealing and elongation, 





2. PCR Cycle begins with denaturing for 5 seconds at 96°C. 
3. Annealing between 50 °C and 62 °C depending on primer specification. 
4. Elongation for 15 seconds at 68°C for 15 seconds PCR Cycle ends.  
5. Repeat steps 2 to 4 for 36 cycles. 
6. Final elongation at 72 °C for 2 minutes. 
1.3.2 Agarose gel electrophoresis 
DNA amplification occurred was confirmed using gel electrophoresis. DNA 
bands are separated by size, the smaller the fragment size the lower it migrates 
down the agarose gel. Since DNA is negatively charged, when applying electric 
current the fragments will move toward the positive electrode. The CoralLoad binds 
to the DNA and emits red fluorescence. A 1% agarose gel made with 1X TAE 
buffer was used (Thermo Fisher 16500100). Prior to casting the gel, propidium 
iodide was added to allow for the visualization of the product. The gels are 
submerged in 1 x TAE buffer (40 mM Tris base, 2 mM EDTA, 20 mM Acetic Acid, 
pH 8.5). Approximately, 2 – 5 µL of the PCR product was loaded along with 2 µL 
of a 100 base pair DNA ladder (Invitrogen™ 100 bp DNA ladder, 15628019). The 
gel was run at 100 volts for 60 minutes and visualized under the Odyssey LI-COR 
scanner.  
1.3.3 Sanger sequence confirmation 
 After confirming that the target region had been properly amplified with gel 
electrophoresis, the amplified genomic DNA from the PCR products were purified 
using the QIAGEN QIAquick PCR Purification Kit (28106).The concentration of the 





reactions were assembled and sent to Genewiz. One reaction consists of 5 µL of 










Table 4: PCR primer sequences for SNP confirmation found apoptosis 
genes.  
Gene SNP  AA Change Forward Reverse 
PIK3C2G rs61757718 *1446S CAGAGCTCCAAGGACATGTC CTGCTTTTAACTGTAGGCACAC 
TP53I3 rs145078765 S252* TCTGAAATCGGGTTCCCTCT AGGCCTCATAAATGGTGAACTT 
TP53AIP1 rs141395772 Q22fs GCAAAAGACCGTCTCGGTTTTC CCTAACAACAAATGAGGAGAAGCCA 
TP53AIP1 rs140191758 S32* GCAAAAGACCGTCTCGGTTTTC CCTAACAACAAATGAGGAGAAGCCA 
BCLAF1 rs61731960 E403* GTTTGACTTCAGGACGGTGA AGGATCAGAGAAAGGGAGGG 
BCLAF1 rs140096922 H847fs TGTAAAACGACGGCCAGT CAGGAAACAGCTATGACC 
PPP1R15A rs139708522 E160* GAGAAACACTGGGGCTGAAA TGTGTGCCTTTTCCTCCTTC 
DOCK1 rs768625958 D248fs AACAGACAAGCCAAGTTTGC GGCAGGCACCATTCTAAATG 
NLRP1 rs771551366 R138fs CCCTATCCTTCCTCTGCTGT GTTGGCCCAATAAAGCACAG 
PTH N/A K85fs TGTATTGTTGCCCTACACTGT TACCTGCAAAAGACATGGCT 
ANGPTL4 rs747940485 G275fs ATGGCTCAGTGGACTTCAAC GCATGTAAGGAAGAGGTGGG 
NOD2 N/A W289* TCAGTCTCGCTTCCTCAGTA TGCAGAAGGTTGAAGAGCAG 





1.4 Cell lines and Cell culture 
A variety of different cell lines were used to find the best in vitro model for 
DNA damage and cell death pathways. Epithelial ovarian cancer cells SKOV-3 are 
derived from a 64-year-old Caucasian female with ovarian serous 
cystadenocarcinoma (Fogh, Fogh, & Orfeo, 1977). SKOV-3-DRGFP cells were 
gifted by Dr. Z Ping Lin from Yale University School of Medicine (Lin, Ratner, 
Whicker, Lee, & Sartorelli, 2014). However, SKOV-3 cells are p53 null and the 
population only exhibited a 2% induction of the DNA repair mechanism. Sub-
cloning was attempted on the SKOV-3-DRGFP cells, but the HRR induction rate 
did not improve significantly. High grade ovarian serous adenocarcinoma 
OVCAR8 cells were also evaluated for functional assessment of DNA repair and 
cell death. OVCAR-8-DRGFP was provided by Dr. Larry Karnitz from the Mayo 
Clinic. However, OVCAR8 is also p53 null and induction of HRR was not 
successful. Therefore, the SKOV4-DRGFP and OVCAR8-DRGFP cells were not 
used for in vitro assessment of DNA repair and cell death.  
HeLa cells are immortalized and derived from cervical cancer cells from a 
31-year-old African American woman. HeLa cells are well characterized and have 
been used across a variety of research topics in the medical fields. HeLa-DR-GFP 
cells were provided by Dr. Jeffery Parvin from Ohio State University. The induction 
of HRR after DNA DSB in HeLa-DRGFP ranged from 10% – 20% of the cells within 
the population. 
All cells types were maintained in Dulbecco’s Modified Eagle Medium 





SH30071.03IR), 1% penicillin-streptomycin (Gibco™, 15070063), and 0.5 - 1.5 
µg/mL puromycin for selection of pDR-GFP (InvivoGen, ant-pr-1).  
1.5 Transfection reagent, siRNA and antibodies 
The focus of this work was to determine the effect of candidate apoptosis 
genes, TP53I3, and the associated nonsense mutation that two of the HBOC 
patients carried on cellular function using transient transfection. Transient 
transfection employs exogenous nucleic acid for a limited period of time followed 
by functional assays. For protein knockdown, high quality and pure siRNAs were 
used targeting the 3’UTR not contained in the plasmid expression vectors. 
Exogenous TP53I3 wildtype, TP53I3-S252* mutant and empty vector DNA 
plasmids were delivered to the cells by transient transfection. All transfections are 
conducted using jetPRIME Transfection Reagent (Polyplus, 114-15). Information 
about plasmid DNA, siRNA protein knockdown, and primary and secondary 
antibodies for protein quantification can be found in Table 5.  Based on knockdown 
efficiency, the concentration of siRNA used for all proteins was 110 picomole/well 






Product Manufacturer Catalog No. Concentration/Dilution 
Hs_ TP53I3_2 FlexiTube siRNA 
20 nmol 
Qiagen SI00069636 110 pmol in a 24 well plate 
Hs_BRCA1_13 FlexiTube 
siRNA 20 nmol 
Qiagen SI02654575 110 pmol in 24 well plate 
P53AIP1 siRNA (h) 10µM Santa Cruz SC-37459 110 pmol in 24 well plate 
Negative Control siRNA 20 nmol Qiagen 1027310 110 pmol in 24 well plate 
PIG3 Antibody- mouse (A-5) Santa Cruz SC-166664 1:1000 overnight incubation  
BRCA1 Antibody- mouse (D-9) Santa Cruz SC-6954 1:200 overnight incubation  
P53AIP1- rabbit Antibody Invitrogen PA5-20355 1:200 overnight incubation  
Beta-actin- rabbit AC-74 
Antibody 
Sigma-Aldrich A53160-100UL 1:10,000 overnight incubation  
Donkey anti-Rabbit IgG (H+L) 
Alexa Fluor® 790 
Thermo Fisher A11374 1:10,000; 1 hour incubation 
Donkey anti-  Rabbit IgG (H+L) 
Alexa Fluor® 680 
Thermo Fisher A10043 1:10,000; 1 hour incubation 
Donkey anti-Mouse IgG (H+L) 
Alexa Fluor® 790 
Thermo Fisher A11371 1:10,000; 1 hour incubation 
Donkey anti-Mouse IgG (H+L) 
Alexa Fluor® 680 
abcam ab175774 1:10,000; 1 hour incubation 
PIG3 cDNA Clone, Human, C-
OFPSpark® tag 
Sino Biological HG15531-ACR N/A 
 






1.6  Cell Lysate Preparation and Western blots 
Identification of specific protein expression from a mixture of proteins can 
be done using the western blotting technique (Mahmood & Yang, 2012). For the 
preparation of protein mixtures, lysed cells and proteins are solubilized using ice-
cold RIPA (Radio Immunoprecipitation Assay Buffer) with Halt™ protease (Thermo 
Fisher, 87786) and phosphatase inhibitor cocktails (Thermo Fisher,  78420). Cells 
are scraped and shaken for 15 minutes at 4ºC. To ensure that the DNA was 
sheared, lysates are passed through a 21-gauge and incubated on ice for 30 
minutes. Cell lysate are centrifuged for 10,000xg for 10 minutes at 4ºC. The total 
cell lysate supernatant was transferred to a new 0.6 mL centrifuge tube. For protein 
concentration, the DC™ Protein Assay was used and consisted of protein assay 
reagent A (Biorad, 5000113), protein assay reagent B (5000114) and protein assay 
reagent S (Biorad, 5000115). Protein concentration was quantified using the 
BioTek Synergy H1 Hybrid Multi-Mode Reader. Prior to loading the gel the protein 
mixture was reduced and denatured using the LI-COR loading buffer and 2-
mercaptoethanol (BME).  
The three main parts of western blot methodology involves separating 
proteins by size, transferring proteins to a membrane and targeting protein for 
visualization with primary and secondary antibodies (Mahmood & Yang, 2012). For 
separation of proteins, a polyacrylamide sodium dodecyl sulfate (SDS) gel was 
used, the size of the protein determines the thickness of the gel. For TP53I3, 
TP53AIP1 and β-actin 12% separating gel was optimal and 6% - 7.5% for BRCA1 





sample buffer (928-40004) and BME before running each gel.  The samples and 
5 µL of the protein standard marker (Biorad, 1610374) were loaded. The gel was 
run at 150 – 180 volts until the dye ran off the gel. The proteins are then transferred 
to a 0.45 µM or 0.22 µM nitrocellulose membrane (VWR) at 250 mA for one hour 
on ice (TP53I3, TP53AIP1, and β-actin) or 30 V for 18 hours at 4ºC (BRCA1).  
Membranes were removed from the transfer apparatus and set to dry for 30 
minutes. Next, the blot was blocked with 5% bovine serum albumin (BSA) in 1x 
Tris Buffered Saline with 0.1% Tween 20 (TBST) for 60 minutes at room 
temperature. The membranes were incubated overnight with the appropriate 
primary antibody diluted in 5% BSA in 1x TBST. The membrane was washed with 
1x TBST for 10 minutes three times. After one hour incubation with the secondary 
in the dark at room temperature, membranes were washed with 1 x TBST for 3 
minutes three times (Table 5).  Visualization and quantification of protein are 
determined by the LI-COR Odyssey® CLx Imaging System.  
1.7 TP53I3 gene editing and transfection 
TP53I3 expression vector, pCMV3-C-OFPSpark-TP53I3, was acquired 
from Sino Biological (HG15531-ACR). The plasmid contains an open reading 
frame for the full coding sequence of TP53I3 followed by an orange fluorescent 
protein (OFP) marker at the C-terminus. Using the wildtype plasmid, site-directed 
mutagenesis was conducted using the Q5-Site-Directed Mutagenesis Kit from 
New England BioLabs Inc. (E0554S). To emulate the mutation change in two of 
our 48 ovarian cancer patients the kit was used to create the rs145078765 (c. 





forward 5ꞌ-CCCCTGTTTTAAAAAGCTACTTTTTAAG-3ꞌ and reverse 5ꞌ-
CCCATTGATGTCACCTCC-3ꞌ. Purified DNA of the selected mutant and wildtype 
clones was conducted using the Qiagen QIAamp DNA mini kit. PCR primers were 
created to sequence the open reading frame of the plasmid in order to capture the 
entire coding region of TP53I3 in both the wildtype mutant plasmid (Figure 6). In a 
60 mm culture plate, a 3 ng/µL concentration of unmodified transfection was 
sufficiently expressed pCMV3-C-OFPSpark-TP53I3 and similar to endogenous to 
TP53I3. The pCMV3-C-OFPSpark-TP53I3 will be addressed as TP53I3-WT and 
the mutant plasmid will be TP53I3-S252*. Due to the orange fluorescent protein 
tag on the C-terminus of the wildtype construct, the size of the exogenous TP53I3-
WT is 64 kDa. Mutated TP53I3-S252* mutation is 28 kDa and endogenous TP53I3 
is 36 kDa. Assessment of the mutant was conducted using a transient transfection 
methodology, where endogenous TP53I3 was depleted with siRNA and the 
TP53I3-S252* plasmid or the TP53I3-WT plasmid or pCMV3 empty vector was 
incorporated into the HeLa-DR-GFP cells. The TP53I3 siRNA targeted a region at 









Figure 6: TP53I3 site-directed mutagenesis for S252* mutant.  
The pCMV3-C-OFPSpark plasmid (A) carries the full coding sequence of TP53I3 
and confirmed with PCR, gel electrophoresis and Sanger sequencing (C). Using 
the NEB Q5® Site-Directed Mutagenesis kit, the cytosine at position 755 of the 
DNA sequence was modified to guanine resulting in a pre-mature stop codon 
exhibited in the OVCA cohort (B). The mutant plasmid DNA was compared to 
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1.8  Homologous Recombination Repair (HRR) Assay 
Hela-DR-GFP cells provided by Dr. Jeffery Parvin from Ohio State 
University School of Medicine are used for in vitro assessment of HRR. Within the 
genome, the cells contain the DR-GFP plasmid which consists of two copies of 
green fluorescent protein (GFP) and transfection of I-Sce1 endonuclease causes 
a DSB in the GFP allele 1 containing the I-Sce1 recognition site. The truncated 
GFP allele 2 serves as a donor of DNA repair, resulting in the activation of the 
repaired GFP allele 1. Therefore, GFP expression is a proxy for HRR occurring in 
the cells (Pierce, Johnson, Thompson, & Jasin, 1999a). To maintain the HeLa-DR-
GFP selection, cells were cultured with 1.5 µg/mL Puromycin (Figure 8). 
Quantification of GFP expression after transfection was determined using the BD 
FACSCanto II at the Wayne State University Microscopy, Imaging & Cytometry 
Resources (MICR) core. To establish how proteins of interest affect the induction 
of HRR, siRNAs are used (Figure 8). As a negative control, empty vector pCMV3 
was used. HeLa-DR-GFP cells were seeded 24 hours prior to transfection. The 
transfection complex consists of pCMV3 empty vector or TP53I3-S252* or wildtype 
TP53I3 with pCBASceI, siRNA and jetprime®PRIME reagent diluted into 
jetPRIME® Buffer.  All conditions were conducted in triplicate for each experiment 








Figure 8: Detailed protocol for HRR assay.  
The HRR assay was conducted in HeLa-DRGFP cells. Knockdown and rescue 





1.9  Colony Survival Assay 
The clonogenic assay can be used to determine a single cell’s ability to 
survive and grow into a colony (Franken, Rodermond, Stap, Haveman, & van Bree, 
2006). The in vitro cell assay can be used to ascertain the cell’s reproductive death 
after being conditioned with various cytotoxic agents (Franken et al., 2006). To 
determine how TP53I3 knockdown, TP53I3-S252* and TP53AIP1 knockdown cells 
respond to chemotherapy agents the colony survival assay was utilized (Figure 9). 
For each condition, 300 cells are seeded in triplicate. Conditioned cells were 
treated with the IC50 of bleomycin (1.5 µM), mitomycin C (100 nM), etoposide (4 
µM) or hydrogen peroxide (H2O2, 125 µM). To prevent the rapid degradation of 
H2O2, it was diluted in phenol red-free and sodium bicarbonate free DMEM. Clones 
were grown for seven days post-treatment then fixed and stained with 0.5% crystal 
violet (Sigma-Aldrich, C0775).  Surviving colonies consisting of 50 or more cells 










Figure 9: Detailed protocol for clonogenic assay 
The clonogenic assay was conducted using HeLa-DRGFP cells. Knockdown and 





2.1  Mitosox assay for mitochondrial reactive oxygen species (ROS) 
production 
To detect for production of ROS in the presence of H2O2 or etoposide, the 
Mitosox probe for intra-mitochondrial superoxide ROS was used (Kauffman et al., 
2016). Mitosox is a positively charged probe that accumulates and emits red 
fluorescence (excitation: 510 nm, emission: 580 nm) in the mitochondria to detect 
for superoxide ROS (Kauffman et al., 2016). For each treatment (H2O2 or 
etoposide), cells were seeded 24 hours prior to transfection with each knockdown 
condition was conducted in triplicate (Figure 10). An additional plate was used to 
serve as an untreated control for knockdown conditions in triplicate.  In parallel 
cells were also seeded in 6 well plates for cell lysate and protein quantification. 
The transfection complex includes TP53I3-252* or TP53I3 wildtype or pCMV3 
DNA with siRNA and jetPRIME® reagent. Cells were then treated with etoposide 
60 µM or 125 µM of H2O2 for four hours. Next, treatment was removed and cells 
were washed three times with warm PBS (37ºC) and then stained with 5 µM 
Mitosox for 30 minutes at 37ºC at 5% CO2 in the dark. Fluorescence intensity was 







Figure 10: Detailed protocol for Mitosox staining 
The mitosox assay was conducted in HeLa cells. Knockdown and rescue 
conditioned cells for protein quantification are conducted in parallel. Untreated and 
treated conditions include, Scramble siRNA + pCMV3 treated, siBRCA1 + pCMV3, 
siTP53AIP1 + pCMV3, siTP53I3 + pCMV3, siTP53I3 + TP53I3-WT plasmid, 






3.1  Statistical Analysis 
The values reported in graphs are the mean±standard error (S.E.) from 
experiments conducted in triplicate. A standard two-way student t-test was 
conducted to compare all conditions to the positive control. A value of p<0.05 was 







CHAPTER 3 – RESULTS  
1.1 Identifying clinically actionable germline mutations in HBOC patients 
From 1999 – 2015, 800 DNA samples of breast and/or ovarian cancer 
patients were collected. I assessed the WES data of the germline DNA of 48 
Caucasian patients suspected to have HBOC but negative for pathogenic 
mutations in BRCA1 and BRCA2. During the period of time in which the samples 
were collected, genetic panel testing had not yet been established as a standard 
of care, as usually only BRCA1 and BRCA2 were analyzed. Therefore, this sample 
subset was an excellent cohort to explore genetic variation associated with OVCA 
because they have not undergone up-to-date genetic panel testing. The WES data 
from these patients can also help identify additional mutations in non-panel genes. 
Variant caller files (VCF) were created for each patient and further annotated using 
the Illumina Variant Studio 3.0 application. All mutations are annotated based on 
ACMG and NCCN guidelines. Variants were filtered to only include those in the 
coding region, with a minor allele frequency of at most 2%.  I focused on truncation 
or missense annotations as well as pathogenic or likely pathogenic in ClinVar, 
damaging or deleterious in Polyphen or SIFT, high or moderate in SnpEff, type 
and definition in COSMIC, germline in TCGA or damaging in HGMD. Five 
unrelated patients carry a clinically actionable mutation (Table 6), including a 
premature stop-gain or frameshift in FANCM, RAD51D or ATM (Stafford et al., 
2017). All five truncations were cross-referenced with the HGMD database and the 
FANCM R1931* (rs144567652, MAF = 0.000946) and RAD51D R206* 





mutations (DM).  Patient OCJ19 carries the FANCM  rs144567652 nonsense 
mutation, and consistent with our study it was associated with an increased the 
risk of triple-negative breast cancer (Figlioli et al., 2019; Peterlongo et al., 2015) 
and hereditary ovarian cancer (Dicks et al., 2017). Additionally, patient OCJ19 
carries a truncating mutation in TP53I3-S252*, an oxidoreductase involved in the 









Table 6: Clinically actionable and novel risk loci in DNA repair genes (Lopes 
et al., 2019; Stafford et al., 2017) 
From left to right is gene name, SNP ID from dbSNP, the mutation was either 
nonsense (*) or frameshift, gnomAD non-Finnish population minor allele frequency 





1.1.1  Novel risk loci in DNA repair, cell cycle regulating and apoptosis 
candidate genes 
To address the issue of missing heritability in HBOC, we conducted targeted 
screening to identify high impact variants in genes not currently on the genetic 
panels. Genetic aberrations disrupting DNA repair, cell cycle regulating and 
apoptosis can result in tumorigenesis. Therefore, variants of interest were 
narrowed down to those found in KEGG annotated as DNA repair, cell cycle 
regulating and/or apoptosis genes (Table 5). There are eleven high impact 
truncations in DNA repair and cell cycle regulating non-panel or “candidate” genes 
(Stafford et al., 2017).  Of particular interest was the TP53I3 S252* rs145078765 
stop-gain mutation caused by the point mutation of a cytosine at position 755 to 
guanine in the gene’s coding sequence (Figure 6). This nonsense mutation was 
present in two unrelated patients, OCG14 and OCJ19. There are multiple 
incidences of epithelial cancers in the family history for both patients including 
ovarian, breast, prostate, pancreatic, stomach and melanoma (Figure 11A and B). 
Patient OCJ19 also carries the FANCM R1931* (rs144567652) truncation (Stafford 
et al., 2017). Her family history includes two members previously diagnosed with 
pancreatic cancer or multiple myeloma (Figure 11A). HBOC syndrome is known to 
increase the risk of prostate, pancreatic, male breast and melanoma in gene 
variant carriers (Solomon, Das, Brand, & Whitcomb, 2012).  Patient OCG14 has 
siblings diagnosed with ovarian, breast, stomach, and eye cancer (Figure 11B). 
Approximately 1-3% of stomach cancer patients have an inherited cancer 





also some family members with unknown cancer diagnoses, an issue that is often 







Gene Consequence Amino Acid Exon SNP ID MAF OBS 
PIK3C2G STOP LOST *1446S 32/32 rs61757718 0.017 2 
TP53I3 STOP GAIN S252* 4/5 rs145078765 0.0016 2 
TP53AIP1 FRAMESHIFT Q22fs 3/4 rs141395772 0.007 1 
TP53AIP1 STOP GAIN S32* 3/4 rs140191758 0.0009 1 
BCLAF1 STOP GAIN E403* 5/13 rs61731960 0.007 1 
BCLAF1 FRAMESHIFT H847fs 2/13 rs140096922 0.0003 3 
PPP1R15A STOP GAIN E160* 2/3 rs139708522 0.006 1 
DOCK1 FRAMESHIFT D248fs 8/52 rs768625958 N/A 1 
NLRP1 FRAMESHIFT R138fs 2/17 rs771551366 0.00007 1 
PTH STOP GAIN K85fs 1/3 N/A N/A 1 
ANGPTL4 FRAMESHIFT G275fs 6/7 rs747940485 0.0002 1 
NOD2 STOP GAIN W289* 4/12 N/A N/A 1 
GZMM STOP GAIN Q161* 4/5 rs200398398 0.014 1 
 
Table 7: Candidate risk mutations in apoptosis genes 
From left to right; Gene name, Consequence = modification due to the mutation, 
Amino acid = translated amino acid change due to nonsense (*) or frameshift (fs) 
mutation, Exon = location of truncation, SNP ID = dbSNP ID, MAF = gnomAD 
non-Finnish population minor allele frequency and OBS = number of patients in 






Figure 11: Patient pedigree for carriers of TP53I3-S252* 
Patient OCJ19 (A) pro-band (arrow) carries TP53I3-S252* and pathogenic variant 
FANCM-R1931* and has a family history of BC and OVCA. (B) Patient OCG14 










As stated previously, the individuals in the HBOC cohort also carry several 
truncations in apoptosis genes.  Several of the truncations in apoptosis genes were 
present in more than one of the 48 HBOC patients (Table 7). Of particular interest 
are 12 truncating mutations in 10 genes, including TP53I3, a TP53-regulated gene. 
TP53I3 is involved in both DNA damage response and p53-mediate apoptosis. To 
date, there has been no germline variant in TP53I3 associated with cancer. 
However, there have been several studies indicating that the gene affects the 
progression of a variety of cancers including outcome of breast (Zhang et al., 
2015), NSCLC (M. Li et al., n.d.), colon (Park et al., 2017) and papillary thyroid (XU 
et al., 2015). TP53I3 overexpression significantly results in an increase in breast 
cancer survival (Zhang et al., 2015). Loss of TP53I3 expression promotes NSCLC, 
colon and papillary thyroid cancer (M. Li et al., n.d.; Park et al., 2017; XU et al., 
2015).  
Tumor Protein P53 Regulated Apoptosis Inducing Protein 1 (TP53AIP1) is 
a mitochondrial protein involved in p53-mediated apoptosis. TP53AIP1 induces the 
release of cytochrome c from the mitochondria and interacts with BCL-2, affecting 
TP53AIP1-mediated apoptosis through regulation of the mitochondrial membrane 
potential (Matsuda et al., 2002; Oda et al., 2000). Reduced expression of 
TP53AIP1 has been associated with increased progression of non-small cell lung 
cancer (Fang et al., 2019). Two unrelated patients carry either the Q22fs 
(rs141395772, MAF=0.007) truncation or the TP53AIP1 S32* (rs140191758, 
MAF=0.0009) variants in TP53AIP1. These two high impact mutations have been 





as to whether the two truncations are associated with prostate cancer risk 
(Luedeke et al., 2012a; Wang et al., 2006).  
Three unrelated patients carry the same nonsense mutation in BCL2 
associated transcription factor 1 (BCLAF1) (rs61731960, E403* MAF=0.007) and 
another patient has a frameshift mutation (rs140096922, H847fs MAF=0.0003) in 
this gene. BCLAF1 is a tumor suppressor that interacts with anti-apoptotic 
members of the BCL-2 family (Cuconati & White, 2002). The BCLAF1- E403* 
nonsense mutation found in our study was previously identified in four unrelated 
individuals of a larger population study of germline and somatic variants in ovarian 
cancer patients (Kanchi et al., 2014). An in vitro study found that colon cancer cells 
deficient in BCLAF1 have decreased cell growth and colony formation. Colon 
cancer cells expressing BCLAF1 were injected into nude mice. Knockdown of 
BCLAF1  resulted in a decrease in tumor incidences and tumor formation (Zhou et 
al., 2014).   
Another mutation over-represented in the cohort was the stop lost in 
Phosphatidylinositol-4-Phosphate 3-Kinase Catalytic Subunit Type 2 Gamma 
(PIK3C2G), which belongs to the phosphoinositide 3-kinase (PI3K) family. The 
gene has a been associated with poor colorectal cancer patient outcome (A. Li et 
al., 2015) and promotion of type 2 diabetes mellitus (Daimon et al., 2008). In the 
case of colorectal cancer, low copy number variants in PIK3C2G resulted in an 
increased risk of reoccurrence and poor survival (A. Li et al., 2015). There are five 





(Daimon et al., 2008). Diabetes negatively affects the overall survival of ovarian 
cancer patients (Shah et al., 2014).  
1.2 Functional Assessment of TP53I3- S252* 
1.2.1 Loss of TP53I3 or TP53I3-s252* significantly decreases homologous 
recombination repair (HRR) 
Many of the genes currently on the HBOC testing panel are involved in DNA 
repair mechanisms. Ovarian and breast cancer panel genes such as ATM, 
BRCA1, BRCA2, CHEK2, PALB2, RAD51D, and RAD50 have important roles in 
the HRR mechanism. For repair of DSB with HRR, the ATM protein detects the 
break and phosphorylates numerous proteins including Chk2 and BRCA1 
(Maréchal & Zou, 2013). A key regulator of ATM activation is the MRN complex 
which consisting of Mre11, Rad50 and Nbs1 (Maréchal & Zou, 2013; Symington, 
2014). Rad51 interacts with BRCA1 and BRCA2 as well as PALB2 to replace RPA 
and form filaments on the DNA. To determine how TP53I3 effects HRR, I used 
HeLa-DR-GFP cells. The pDR-GFP plasmid contains two inactive green 
fluorescent protein (GFP) allele, one has the SCE-1 endonuclease recognition site 
and the other is truncated. Upon transfecting HeLa-DR-GFP cells with pCBASce1, 
a DSB occurs and the truncated allele serves as a template for HRR of the lesion 
and activation of GFP (Pierce, Johnson, Thompson, & Jasin, 1999b). This assay 
was employed to determine whether loss of TP53AIP1, TP53I3, and TP53I3-S252* 
mutation effects HRR (Figure 12). Because BRCA1 is well established to have a 
primary role in the HRR mechanism, it is expected that knockdown of the 





BRCA1 siRNA knockdown condition was used as a concurrent control for the 
transient co-transfections of the siRNA-test gene and the pCBASCE1 plasmid.  
Overall, knockdown of TP53I3 significantly reduced by an average of 20% (p-value 
≤ 0.05) HRR.  Attempting to rescue wildtype TP53I3 after knockdown was 
successful, similar experiments with TP53I3-S252* also succeeds, but to a lesser 
extent, indicating that the presence of the truncation negatively impacts its role in 
HRR (p-value ≤ 0.05). Although the impact of TP53I3 (p-value ≤ 0.05) on HRR was 
not as significant as panel gene BRCA1 (p-value ≤0.001), it has a similar effect to 
other panel genes like CHEK2 and ATM (Lopes et al., 2019). The depletion of 
TP53AIP1 with siRNA did not result in a significant reduction in HRR. This is 
consistent with the primary function of the protein in p53-mediated apoptosis and 







Figure 12: TP53I3-S252* significantly defects Homologous Recombination 
Repair 
HeLa-DRGFP cells contain the p-DRGFP plasmid which has two inactive GFP 
alleles. The SCE-1 endonuclease recognition side is located in the first allele and 
the second allele is truncated. Introduction of pcBASce-1 to the cells causes a 
double stranded break in the first GFP allele and the second GFP allele acts a 
template for HRR of the lesion. Active GFP is a proxy for HRR having occurred in 







with wildtype (TP53I3 WT) or mutant plasmid (TP53I3 S252*). (B) Fluorescent 
imaging of HeLa-DRGFP cells repairing DSB (after pCBASce1 transfection) with 
HRR compared to empty vector pCMV3. (C) Western blots for knockdown of 






1.2.2 TP53I3 deficient cells are sensitive to mitomycin C, bleomycin and 
etoposide 
Chemotherapy agents often given to HBOC patients were used, including 
mitomycin c (MMC), bleomycin and etoposide. To determine how TP53I3 and 
TP53I3-S252* affect drug response and cell death, the clonogenic assay was 
employed. Because BRCA1 is a known HBOC panel gene, knockdown of the 
protein with siRNA in HeLa-DRGFP cells was used to ensure siRNA transfection 
could affect a drug response on cell survival. I determined the IC50 dosages to be 
100 nM for mitomycin C (MMC), 1.5 µM for bleomycin and 4 µM for etoposide, 
administered for four hours. In the absence of these cytotoxic agents knockdown 
of BRCA1 and TP53I3 exhibited, respectively, 20% or 18% loss in  the number of 
viable clones (p-value ≤ 0.05) (Figure 13).  
As expected BRCA1-deficient HeLa cells exhibited significant additional 
sensitivity to MMC (p-value ≤ 0.001), bleomycin (p-value ≤ 0.001), and etoposide 
(p-value ≤ 0.001). In the case of etoposide, there is an almost complete absence 
of viable clones.  Following a similar trend, loss of TP53I3 resulted in the cells 
being significantly more sensitive (p-value ≤ 0.05) to all three drug treatments 
(Figure 14). Approximately 60% of the cells survived after TP53I3 knockdown, 
compared to the 80% in the scramble control (p-value ≤ 0.05). About 80% of cells 
survived after knockdown of endogenous TP53I3 and rescue with the wildtype 
plasmid. Similar to the scramble control. Knockdown of TP53I3 with siRNA and 
attempted rescue with the TP53I3-S252* mutant plasmid resulted in a slight 







Figure 13: TP53I3-S252* and TP53AIP1 reduces cell death 
(A) Plating efficiency after knockdown of proteins and introduction of empty vector 
(pCMV3), wildtype TP53I3 (TP53I3-WT), or S252* mutant (TP53I3-S252*). (B) 



















***p-value ≤ 0.001 
**p-value≤0.01 





Figure 14: TP53I3-S252* resistant to OVCA chemotherapy  
 (A) Surviving fraction after treatment with bleomycin, MMC or etoposide 
incorporates plating efficiency. Representative images of surviving clones after 
knockdown of protein of interest and introduction of empty vector (pCMV3), 
wildtype TP53I3 (TP53I3-WT) or TP53I3 S252* mutant (TP53I3-S252*) after 





1.2.3 TP53I3 S252* resistant to mitomycin C, bleomycin and etoposide 
The depletion of endogenous TP53I3 and rescue with exogenous TP53I3-
S252* causes in a slight increase in the number of surviving clones compared to 
the scrambled control (Figure 13). There was a significant increase in the number 
of surviving clones after treatment with MMC (p-value ≤ 0.001) or etoposide (p-
value ≤ 0.001), displaying the resistance of the mutation to DNA damaging agents 
(Figure 14A, C and D). This phenomenon could be explained by the mutant cells 
multiplying and becoming more resistant to chemotherapy, gene amplification, 
disruption of drug transportation across the cell wall, an alternative method of DNA 
break repair or inactivation of the drug in the presence of the mutant. After 
bleomycin treatment, an increase in the number of clones is observed but not 
significantly. 
1.2.4 TP53AIP1 response to mitomycin C, bleomycin and etoposide 
The knockdown of TP53AIP1 did not significantly change the number of 
surviving clones compared to scramble control (p-value = 0.595, Figure 13). 
Similar to TP53I3-S252* cells, depleted TP53AIP1 HeLa-DRGFP cells were 
resistant to mitomycin C (p-value ≤ 0.01) or etoposide treatment (p-value ≤ 0.01) 
(Figure 14A, C and D). An opposite response was observed after bleomycin 
treatment, with a significant decrease in surviving clones (p-value ≤ 0.05) (Figure 
14A and B). Bleomycin is a radiomimetic drug that inhibits the synthesis of DNA, 
indicating that a selective sensitivity to this drug by TP53AIP1 could provide a 





1.2.5 TP53I3-S252* increases cell viability in the presence of oxidative stress 
TP53I3-S252* may contribute to the resistance of chemotherapy often 
given to HBOC patients. To further explore this finding, the clonogenic assay was 
also utilized to determine how the mutation could affect cell death, due to TP53I3’s 
role in ROS production and p53-mediated apoptosis. Hydrogen peroxide (H2O2) 
has a well-defined role in apoptosis induction and ROS production by increasing 
the formation of superoxide and hydroxyl radicals. Knockdown of TP53I3 in HeLa 
cells followed by a four-hour H2O2 treatment (125 µM), did not change colony 
formation compared to scramble control (Figure 15). However, in the presence of 
TP53I3-S252* after endogenous TP53I3 knockdown and exposure to H2O2, there 
was a significant increase in colony formation (p-value ≤ 0.001). This suggests the 
mutant disrupts a conversed region of the protein which, under wildtype conditions, 
is involved in activating cell death. The mutant is adjacent to conserved residues 
that make up the active binding site that interacts with QOR substrates for the 
formation of ROS and resulting in eventual apoptosis (Porté et al., 2009). Under 
conditions of TP53AIP1 knockdown and subsequent treatment, there was no 








Figure 15: TP53I3 - S252* response to oxidative stress 
(A) Surviving fraction after treatment with H2O2 expressed in terms of plating 
efficiency. (B) Representative qualitative images of each knockdown condition with 





***p-value ≤ 0.001 
**p-value≤0.01 





1.2.6 TP53I3-S252* decreases ROS production in the presence of H2O2 or 
etoposide 
 The unique response of TP53I3-S252* in the clonogenic assay begs the 
question of what mechanism is preventing cell death. TP53I3 has been described 
as a member of the quinone oxidoreductase gene family that can catalyze the 
formation of superoxide and hydroxyl ROS. The MitoSox probe allows for the 
quantification of the induction of ROS bodies in the mitochondria. H2O2 and 
etoposide had the most prominent effect on cell proliferation in the presence of 
TP53I3-S252*. Also, both superoxide producing H2O2 and topoisomerase II 
inhibitor etoposide have a well-defined role in ROS production (Wu & Yotnda, 
2011). The response to etoposide was of particular interest because of it is 
frequently employed in the treatment of a many cancers, including those seen in 
HBOC high-risk subjects. HeLa cells depleted of TP53I3 or TP53AIP1 significantly 
increased the production of ROS after exposure to H2O2 (p-value ≤ 0.05, Figure 
16). In contrast, there was a decrease in ROS production in the presence of 
TP53I3-S252* and treatment with H2O2 (p-value ≤ 0.05) or etoposide (p-value ≤ 
0.05, Figure 16). This is likely due to the fact that the truncation interrupts 3 
downstream nucleotides that are conserved and part of the active binding site that 






Figure 16: TP53I3-S252* disrupts mitochondrial ROS production 
Proteins of interest were knockdown in HeLa cells (without DR-GFP) and/or 
rescued with TP53I3 wildtype or TP53I3-S252* followed by treatment with H2O2 or 






CHAPTER 4 – DISCUSSION  
1.1 Whole exome sequencing is a more powerful tool for genetic risk 
assessment than a traditional candidate gene approach 
Whole exome sequencing provides an enriched data set to identify disease 
risk loci. In the past decade, there has been an influx of larger and more inclusive 
gene panels, but the issue of low diagnostic yield and missing heritability remains 
(Chaudhry et al., 2017). As genetic panels are being continuously updated and 
with a rapid decrease in the cost of WES/WGS it would be beneficial to take a NGS 
approach to identify an individual’s true genetic risk. This study has been able to 
demonstrate the benefits of utilizing WES data of high-risk hereditary breast and 
ovarian cancer patients.  Variant assessment of WES resulted in the identification 
of clinically actionable mutations and post hoc assessment of candidate risk loci in 
DNA repair and cell cycle regulation. In addition, the findings in this thesis implicate 
apoptosis genes and the apoptosis pathway as a whole to be important in 
addressing the issue of missing heritability in HBOC.   
 Traditionally, patients undergo genetic panel testing involving high 
throughput sequencing of target genes. When using WES all genes on a panel test 
can be assessed and the data can be mined any time in the future when additional 
novel risk loci are identified. We found five clinically actionable genetic variants 
(Lopes et al., 2019; Stafford et al., 2017) in our cohort of 48 HBOC patients. An 
exciting finding among them was the FANCM R1931*(rs144567652) nonsense 
mutation. The FANCM gene is not on any cancer genetic panel, but there is a 





specifically involved in the recognition of interstrand cross-links (ICL) and recruits 
BRCA1 for downstream DNA repair by HRR  (Whitby, 2010; Xue, Sung, & Zhao, 
2015). Additionally, consistent with our findings (Chaudhry et al., 2017; Lopes et 
al., 2019; Stafford et al., 2017) the rs144567652 variant was found to increase the 
risk of triple-negative breast cancer (Figlioli et al., 2019; Peterlongo et al., 2015) 
and hereditary ovarian cancer (Dicks et al., 2017).  
1.2 The necessity to assess cell death pathway genes for genetic risk 
assessment of cancer  
From our OVCA cohort, there was an enrichment of rare, high impact 
mutations in apoptosis genes. Many of these truncated genes already have an 
association with a variety of cancers. Two unrelated OVCA patients carry either 
the rs141395772 or rs140191758 truncation in TP53AIP1. Both these SNPs have 
been previously associated with melanoma (Benfodda et al., 2018) and could be 
considered VUSs due to opposing reports on the effect of the mutations on 
prostate cancer (Luedeke et al., 2012b). There was an overrepresentation of 
truncations in BCL2 in our cohort, with four of the patients carrying rs140096922 
or rs61731960.  Given BCL2’s prominent role in the regulation of apoptosis and 
mitochondrial membrane potential, defects in its protein function can have 
detrimental defects to a variety of programmed cell death and DNA repair 
mechanisms. A total of 18 patients carried a truncated apoptosis gene, as well as 
the patients carrying 11 high impact DNA repair truncations. Apoptosis is a tightly 
controlled and conserved mechanism, and therefore programmed cell death 





1.3 TP53I3 has an important role in DNA damage and apoptosis 
Two of the HBOC patients carry a rare, premature stop gain mutations 
S252* in TP53I3. Based on overexpression, knockdown or allele frequency,this 
gene has been associated with squamous cell carcinoma of the breast (Gorgoulis 
et al., 2004), squamous cell carcinoma of the head and neck (Guan et al., 2013), 
myeloid leukemia (Nomdedéu et al., 2004), lung (Gorgoulis et al., 2004) and 
invasive bladder (Ito et al., 2006). However, there has yet to be an example of 
germline mutational changes in TP53I3 associated with disease risk in cancer 
patients. The gene is important to mechanisms associated with maintaining the 
integrity of DNA and cellular homeostasis. The mechanisms include TP53I3 being 
transcriptionally regulated  by TP53 (A Kotsinas et al., 2010) for response to DNA 
damage (Lee et al., 2010) and apoptosis (Flatt et al., 2000). TP53I3 is a quinone 
oxidoreductase involved in redox reaction to continuously produce ROS, vital to 
maintaining cellular homeostasis (Bolton & Dunlap, 2017; Oppermann, 2007; 
Porté et al., 2009).  Therefore, mutations genes involved in the pathways can have 
detrimental consequences for cells to properly function (Jeggo, Pearl, & Carr, 
2016). TP53I3 is considered to be an upstream regulator of the DDR pathway, 
which, unlikeTP53, are rarely altered. So the potential of a positive feedback loop 
of TP53I3 being p53 transcriptionally activated and its role DDR will likely not be 
compromised because mutated p53 is enough to effect repair and cell death 
mechanisms. In short, loss of TP53I3 would have a negative impact on both normal 
and cancer cells (Athanassios Kotsinas et al., 2012). Therefore, mutations in this 





The TP53I3-S252* mutation is in the fourth exon and in its presence, the 
cells did not rescue DDR, demonstrated a decrease in ROS production, and a 
resistance to cell death in the presence of cytotoxic agents. The PIG3AS is a splice 
variant for TP53I3 in which exon 4 is spliced out, resulting in an inactive protein. A 
functional consequence of when the splice variant is preferentially translated is the 
disruption of ROS formation. This is due to the absence of the C-terminus 
sequence, which is homologous with a QOR a subclass of the MDR superfamily 
(Nicholls et al., 2004). Additionally, the missense mutation of serine at position 151 
to valine in the protein disrupts a conserved binding motif for NADP+ 
(A/G)XXSXXG (Edwards et al., 1996). This makes the protein enzymatically 
inactive because of steric hindrance and not allowing NADP+ to bind.  In the 
presence of substrate quinone 1,2-NQ and cofactor NADPH, there was a decrease 
in binding affinity to the enzyme resulting in a loss of ROS production (Porté et al., 
2009). The presence of the TP53I3-S252* mutation at the fourth exon resulted in 
a truncation due to a nonsense mutation. There are two possible explanations as 
to why the mutant exhibits opposing phenotypes of ROS production and cell death 
when comparing scramble siRNA to TP53I3 siRNA knockdown. Either there was 
a loss of the enzymatic ability to the TP53I3 due to the truncation or the mutation 
has a dominant negative effect that changes ROS production and cell death.  
The location of the nonsense mutation is in position 252 of the TP53I3 
protein sequence, where serine is altered to a premature stop codon. At the very 
least, this nonsense mutation found in TP53I3 shortens the protein and it is 





enzymatic ability of the protein. Recall that the residues involved in the active site 
include Leu255, Phe256, and Leu265 (Porté et al., 2009). TP53I3 is disrupted by 
a nonsense mutation found in two of the OVCA patients which prevents the 
translation of the mRNA sequence after position 252. This means that three of the 
15 residues necessary for the enzymatic activity of TP53I3 are not present. This 
likely affects the active site conformation, preventing quinone substrates like 1,2-
NQ from binding efficiently, if at all. Also, the ability to reduce free molecular 
oxygen to produce ROS species in the presence of a cofactor is severely 
diminished. This is supported by the fact that TP53I3-S252* cells had a significant 
decrease in mitochondrial ROS production in the form of H2O2, which can be 
reduced to hydroxyl radicals (Figure 16). Furthermore, I observed that in the 
presence of H2O2 the TP53I3-S252* cells experienced less cell death than wildtype 
TP53I3 (Figure 15). After the administration of chemotherapy drugs bleomycin, 
MMC or etoposide there was also a resistance to cell death in the TP53I3-S252* 
mutant cells compared to the scramble control (Figure 14). In the case of MMC 
and etoposide, there was a significant increase in the number of surviving cells in 
the presence of the nonsense mutation in TP53I3. To maintain normal cellular 
homeostasis, high levels of cellular ROS should lead to the activation of 
programmed cell death such as apoptosis. The inability to regulate apoptosis can 
result in the accumulation of old and damaged cells, which will could lead to 
tumorigenesis.   
An alternative hypothesis could be that a dominant negative phenotype is 





phenotype is when the mutant outcompetes the wildtype. The dominant negative 
observed by the mutant in the presence of MMC, etoposide or H2O2 could be due 
to the disruption in the area of the protein responsible for oxidoreductase of 
superoxide ROS (Figure 14 and 15).   This is further suggested by the reduction 
of mitochondrial superoxide ROS after H2O2 treatment in the presence of TP53I3-
S252* (Figure 16). A particular surprising observation is an increase in ROS 
production after TP53I3 knockdown. The TP53I3 siRNA targets the 3’UTR, which 
is outside of the region that is homologous with the MDR superfamily. Since siRNA 
knockdown is not a complete knockout of protein function and there is no disruption 
of the residues involved in the conformation of the active site, the TP53I3 siRNA 
would therefore not hinder the effects of cells undergoing ROS production (Figure 
16) and eventual cell death (Figure 14 and 15).   The opposing effects on cell death 
and oxidative stress when comparing TP53I3 knockdown cells to TP53I3-S252* 
cells depletion of TP53I3 and TP53I3-S252* suggests a dominant negative pattern. 
Tumor suppressor genes  p53 (Willis, Jung, Wakefield, & Chen, 2004) and BRCA1 
(Thangaraju, Kaufmann, & Couch, 2000) and ATM (Chenevix-Trench, 2002) 
genes are known to have dominant-negative mutations that result in carcinomas. 
However, due to the fact that TP53I3-S252* mutation is positioned adjacent to 
three amino acid residues necessary for the integrity and confirmation of the active 
binding site of quinone substrates, it is more likely that mutation is affecting 





Chapter 5 – LIMITATIONS AND FUTURE DIRECTIONS 
 
This study extended the scope of our previously published work to examine 
apoptosis associated genes role in cancer risk. A larger set of missense mutations 
in apoptosis associated genes were also identified and passed the computational 
filters applied including low MAF, high read quality, annotated as deleterious or 
possibly deleterious by Polyphen, Sift or SnpEff and found in clinical databases 
ClinVar, ACMG, COSMIC, TCGA, SNPEff. This is a dataset that can answer 
questions about polygenetic effect where there are multiple medium or low impact 
mutations observed in cancer patients. Additionally, pathway analysis of the HBOC 
patients against a normal population from a database such as 1000genome or 
TCGA would also shed light on other mechanisms that are often overlooked.  
 While the second portion of this project focused on the functional 
assessment of TP53I3-S252* mutation, there were several other high impact 
mutations found in apoptosis genes. Some of the mutations were found in multiple 
patients like those in TP53AIP1, BCLAF1, and PIK3C2G. These genes are 
involved in programmed cell death. To determine the effect of the truncations found 
in the OVCA patients, similar experiments to those used for TP53I3-S252* can be 
used. This would include, the clonogenic assay using DNA damaging and 
apoptosis cytotoxic agents, the Annexin V assay, and mitochondrial membrane 
potential-dependent assay.   
 
To further support the hypothesis that TP53I3-S252* is enzymatically 





cofactor NADPH would be required. Comparing the effect of the truncation at 
amino acid to the known inactivating TP53I3-S151V would also be beneficial and 
to determine if the deficiency in substrate binding is similar. Testing to see how 
both intercellular and mitochondrial ROS is affected by both mutants will also help 
assess the severity of the nonsense truncation on oxidative stress response and 
downstream apoptosis. To directly determine the effect of TP53I3-S252* on 
apoptosis, the Annexin V assay can be utilized in the presence of similar cytotoxic 
drugs used in this study. It would be important to include a drug that is considered 
a positive control for apoptosis, such as camptothecin (CPT). CPT leads disrupts 
mitochondrial membrane potential, resulting in the release of cytochrome c 
release, caspase-3 activation, and ROS formation. TP53I3-S252* and TP53I3-
S151V expressing TP53I3 knockout cell lines would also be advantageous for the 
above mentioned experiments to determine the heterozygote and homozygote 
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A quarter of all cases of ovarian cancer (OVCA) cases are associated with 
inherited risk. However, due to unclassified variants or variants of unknown 
significance (VUS), much of an individual hereditary risk remains unknown. We 
have established the importance of whole exome sequencing to answer the 
question of missing heritability. Five clinically actionable and eleven novel risk loci 
in the DNA repair and cell cycle regulation pathways were identified by in silico  
SNP assessment of a cohort of women diagnosed with OVCA, wildtype for 
BRCA1/BRCA2 and suspected to be hereditary due to family history of breast 
cancer/OVCA. Equally as important was the exploration and discovery of novel 
risk loci in the apoptosis pathway. A total of thirteen truncating mutations in 
apoptosis genes were found in over 35% of our patient cohort. The TP53I3-S252* 
premature stop gain was identified in two unrelated patients, one of whom also 
carries the clinically actionable truncating variant in FANCM. The proposed 





transcriptionally activated by p53 to cause ROS induced apoptosis. It has been 
hypothesized to be a key gene that connects DNA repair mechanisms with 
downstream apoptosis as a quinone oxidoreductase. Additionally, two truncations 
in TP53AIP1, two in BCLAF1 and one in PIK3C2G were identified in multiple 
individuals. This study highlights the importance of the often overlooked pathway 
of apoptosis. The importance of genetic assessment of the apoptosis pathway was 
further strengthened back the observation that TP53I3-S252* significantly 
decreases homologous recombination repair (HRR) and significantly resists 
response to chemotherapy drugs bleomycin, mitomycin c (MMC) and etoposide. 
Additionally, in the presence of oxidative stress from hydrogen peroxide and/or 
etoposide there was a reduction in the formation of reactive oxygen species, which 
is an important precursor to apoptosis. Lastly, the combination of computational 
and bench lab techniques allows for a streamlined assessment of an individual’s 
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